TR-14035

• Description:

  TR-14035 is a orally active dual α4β7/α4β1 integrin antagonist, with IC50 s of 7 nM and 87 nM for α4β7 and α4β1, respectively. TR-14035 can be used for the research of inflammation and autoimmune diseases[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Integrin

• Type:

  Reference compound

• Related Pathways:

  Cytoskeleton

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/TR-14035.html

• Purity:

  99.87

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  COC1=C(C2=CC=C(C[C@@H](C(O)=O)NC(C3=C(Cl)C=CC=C3Cl)=O)C=C2)C(OC)=CC=C1

• Molecular Formula:

  C24H21Cl2NO5

• Molecular Weight:

  474.33

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Sircar I, et al. Synthesis and SAR of N-benzoyl-L-biphenylalanine derivatives: discovery of TR-14035, a dual alpha (4) beta (7) /alpha (4) beta (1) integrin antagonist. Bioorg Med Chem. 2002 Jun;10 (6) :2051-66.|[2]Egger LA, et al. Alpha (4) beta (7) /alpha (4) beta (1) dual integrin antagonists block alpha (4) beta (7) -dependent adhesion under shear flow. J Pharmacol Exp Ther. 2002 Jul;302 (1) :153-62.|[3]Julio Cortijo, et al. A small molecule, orally active, α4β1/α4β7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats. Br J Pharmacol. 2006 Mar; 147 (6) : 661–670.|[4]M Tsuda-Tsukimoto, et al. Pharmacokinetics and metabolism of TR-14035, a novel antagonist of a4ss1/a4ss7 integrin mediated cell adhesion, in rat and dog. Xenobiotica

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• Isoform:

  α4β1; α4β7

• CAS Number:

  [232271-19-1]